-
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1
08 Apr 2025 19:43 GMT
… .1 Today’s FDA decision converts this second … trials.
OPDIVO® (nivolumab) is indicated for the treatment … pain (41%), diarrhea (39%), cough (37%), decreased appetite (35% … collaboration agreement to jointly develop and commercialize multiple immunotherapies …
-
Global Congestive Heart Failure Drugs Market Witnesses Robust Growth Amid Rising Heart Failure Cases
08 Apr 2025 14:33 GMT
… competitive landscape and key developments, policies, manufacturing costs, … the market. These medications are known for their … increasing number of clinical trials and regulatory approvals, … effective treatments and the entry of generic drugs further …
-
AbbVie Announces European Commission Approval of RINVOQ® for the Treatment of Adults with Giant Cell Arteritis
08 Apr 2025 07:55 GMT
… , and SELECT-GCA trial investigator. "Results … treatment of TB. Patients should be monitored for the development … healthcare professional if medication residue is observed … bronchitis, nausea, neutropenia, cough, AST increased, and hypercholesterolemia …
-
Congestive Heart Failure Drugs Market Poised for Strong Growth Amid Rising Cases of Heart Failure
08 Apr 2025 05:30 GMT
… trials are also creating new opportunities in CHF treatment. … for CHF drugs.
Commonly used medications such as … in drug development, including combination therapies and treatments targeting specific … effects such as persistent cough. ARBs offer similar …
-
AI-Designed Drug for IPF Gets Name, Fares Well in Early Trials
08 Apr 2025 04:03 GMT
… in AI-driven drug development.
“The name Rentosertib … life measures such as cough reduction and overall respiratory … to initiate larger pivotal trials.
According to Zhavoronkov, … patients, potentially transforming the treatment landscape for IPF.
IPF …
-
Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences
07 Apr 2025 20:30 GMT
… Inhaled Molgramostim for the Treatment of Autoimmune Pulmonary Alveolar … -2 Phase 3 Clinical Trial
Session: English Poster Discussion … of breath, often with cough and frequent fatigue. Patients … CSF) in Phase 3 development for autoimmune pulmonary alveolar …
-
New guidelines aim to improve diagnosis and treatment of mycoplasma pneumoniae in children
07 Apr 2025 16:27 GMT
… droplets, leading to prolonged cough, fever, and breathing … clinical research.
Beyond medications, the guidelines address … Some children with MPP develop increased D-dimer … trials. Additionally, while the guidelines primarily focus on diagnosis and treatment …
-
Targeting twin weaknesses: New research paves way for enhanced whooping cough vaccines
06 Apr 2025 13:07 GMT
… research that could revolutionize whooping cough vaccines, bringing the eradication of … in the research and clinical trial phases,” stated Jennifer Maynard, … avenue for developing therapeutic treatments for infants already infected with whooping cough or …
-
Comparative Analysis of the Efficacy of Abrocitinib and Dupilumab in the Treatment of Atopic Dermatitis
05 Apr 2025 14:48 GMT
… patients experienced cough, 12 had allergic rhinitis, and 9 developed allergic … alongside clinical effectiveness when making treatment decisions, particularly in healthcare … the current literature and clinical trials. Drugs Today. 2022;58(8):373 …
-
New research boosts future whooping cough vaccines
05 Apr 2025 11:08 GMT
… severe symptoms associated with whooping cough.
The new research, … in the research and clinical trial phases," said Jennifer … actively seeking partnerships to develop ways to prevent lung … the importance of prevention over treatment. "It's …